ONTARIO, Calif., April 14, 2004 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced that they have completed the initial phase of the re-start plans for product launch of the enhanced LifePoint(r) IMPACT(r) Test System.
"We are pleased to announce that LifePoint has recently completed shipping product to all our current U.S. law enforcement and industrial workplace customers. They are now able to routinely use the IMPACT Test system again", stated Linda H. Masterson, President and CEO of LifePoint Inc. "Additionally, we have also completed initial product shipments to all of our international distributors, which now allows them to re-initiate their marketing and sales efforts overseas and to re-start the international studies."
Ms. Masterson added, "More importantly, we have now initiated shipping of product to new U.S. law enforcement and industrial customers and new international distributors that have been patiently waiting for the IMPACT Test System availability. We look forward to a very exciting fiscal year for LifePoint, which started on April 1, 2004."
About LifePoint, Inc.
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT Test System -- a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future: ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets -- law enforcement, industrial workplace and medical emergency room -- are estimated to be over $1.6 billion in total opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the potential need for additional financing, FDA 510(k) clearance in medical markets, dependence on third parties for certain marketing efforts, and market acceptance. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc.